These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis - established and novel therapeutic approaches. Ehling R; Berger T; Reindl M Cent Nerv Syst Agents Med Chem; 2010 Mar; 10(1):3-15. PubMed ID: 20236038 [TBL] [Abstract][Full Text] [Related]
6. [Immunosuppression with monoclonal antibodies in multiple sclerosis]. Vermersch P; Zéphir H Rev Neurol (Paris); 2007 Jun; 163(6-7):682-7. PubMed ID: 17607190 [TBL] [Abstract][Full Text] [Related]
7. [Development of new therapies for multiple sclerosis]. Holmøy T; Celius EG Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088 [TBL] [Abstract][Full Text] [Related]
8. New and emerging treatment options for multiple sclerosis. Polman CH; Uitdehaag BM Lancet Neurol; 2003 Sep; 2(9):563-6. PubMed ID: 12941579 [TBL] [Abstract][Full Text] [Related]
9. Leukocyte depletion for leukaemia and multiple sclerosis. Bonn D Mol Med Today; 1998 Dec; 4(12):508. PubMed ID: 9866817 [No Abstract] [Full Text] [Related]
10. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
11. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Fernández Ó Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479 [TBL] [Abstract][Full Text] [Related]
12. Melanoma following treatment with alemtuzumab for multiple sclerosis. Pace AA; Zajicek JP Eur J Neurol; 2009 Apr; 16(4):e70-1. PubMed ID: 19222552 [No Abstract] [Full Text] [Related]
14. Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. Risitano AM; Serio B; Selleri C; Rotoli B Ann Hematol; 2009 Dec; 88(12):1261-2. PubMed ID: 19430789 [No Abstract] [Full Text] [Related]
15. [Multiple sclerosis, the therapeutic arsenal of today and tomorrow]. Zéphir H Soins; 2009 Nov; (740):39-41. PubMed ID: 20014532 [No Abstract] [Full Text] [Related]
16. Clinical trials with CAMPATH-I and other monoclonal antibodies. Hale G; Phillips JM Biochem Soc Trans; 1995 Nov; 23(4):1057-63. PubMed ID: 8654681 [No Abstract] [Full Text] [Related]
17. Monoclonal antibodies in the treatment of multiple sclerosis. Di Pauli F; Berger T; Reindl M Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782 [TBL] [Abstract][Full Text] [Related]
18. Buzz around Campath proof-of-concept trial in MS. Osborne R Nat Biotechnol; 2009 Jan; 27(1):6-8. PubMed ID: 19131976 [No Abstract] [Full Text] [Related]
19. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]. Warnke C; Kieseier BC; Zettl U; Hartung HP Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065 [TBL] [Abstract][Full Text] [Related]
20. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Coles A; Deans J; Compston A Clin Neurol Neurosurg; 2004 Jun; 106(3):270-4. PubMed ID: 15177782 [No Abstract] [Full Text] [Related] [Next] [New Search]